First published as: Naomi Pearce, Dr Jennifer Enmon and Kadri Elcoat, 'New Thinking for New Science -...
New Thinking for New Science- Biopharmaceutical Patent Disputes in Australia
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Pearce IP BioBlast™: w/e 26 Jun 2020
Significant biosimilar activities this week include June 20 | The NZ Herald reported a new study by NZ scientists...
Pearce IP BioBlast™: w/e 12 Jun 2020
Significant biosimilar activities this week include 08 Jun 20 | The Centre for Biosimilars reported that the WHO...
Pearce IP BioBlast™: w/e 05 Jun 2020
Significant biosimilar activities this week include 29 May 20 | In a filing to the Securities and Exchange...
Pearce IP BioBlast™: w/e 29 May 2020
Significant biosimilar activities this week include 25 May 20 | The American Journal of Managed Care reported two cost...
Pearce IP BioBlast™: w/e 22 May 2020
Significant biosimilar activities this week include 11 May 20 | AstraZeneca announced it had recovered the global...
Pearce IP BioBlast™: w/e 15 May 2020
Significant biosimilar activities this week include 11 May 20 | Healio reported on a new study comparing faricimab to...
Pearce IP BioBlast™: w/e 08 May 2020
Significant biosimilar activities this week include 01 May 2020 | AbbVie released its Q1 2020 financial results,...
Pearce IP BioBlast™: w/e 01 May 2020
Significant biosimilar activities this week include 23 April 2020 | Henlius Biotech announced it has received two EU...
Pearce IP BioBlast™: w/e 24 Apr 2020
Significant biosimilar activities this week include 21 Apr 20 | The Centre for Biosimilars reported that Xbrane Pharma...
Pearce IP BioBlast™: w/e 17 Apr 2020
Significant biosimilar activities this week include 14 April 20 | Mylan and Biocon launched Fulphila® (pegfilgrastim)...
Pearce IP BioBlast™: w/e 10 Apr 2020
Significant biosimilar activities this week include March 20 | BiosanaPharma released the results of Ph I trials of...
Pearce IP BioBlast™: w/e 03 Apr 2020
Significant biosimilar activities this week include 30 Mar 20 | Biocad announced it had received registration...
Pearce IP BioBlast™: w/e 27 March 2020
Significant biosimilar activities this week include March 20 | The UK High Court ruled filing errors in a...
Pearce IP BioBlast™: w/e 20 March 2020
Significant biosimilar activities this week include 16 Mar 20 | Teva and Celltrion launched Herzuma (trastuzumab) in...
Centre for Biosimilars reports biosimilar bills introduced to US Congress
On 19 March 2020, the Centre for Biosimilars reported on a pair of biosimilar bills which were introduced to the US...